Here are updates on two of your buys

Article Excerpt

Long-time readers know that we aim to keep you informed of important news about the stocks we cover. That means highlighting developments and plans that promise to bolster investor gains. Here are two buys that stand out this month: ELI LILLY & CO., $757.18, is still a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares outstanding: 948.0 million; Market cap: $717.8 billion; Dividend yield: 0.8%) has now partnered with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial weight-loss medicine Zepbound (tirzepatide) to their patients in virtual care weight loss management programs. The companies are directly contracting with Eli Lilly’s self-pay pharmacy, GiftHealth. The move could be a plus for telehealth weight loss programs, which have proved lucrative for companies like LifeMD and Teladoc Health. The announcement follows Eli Lilly’s partnership with telehealth platform Ro three months ago. The pharmaceutical company also launched its own direct-to-consumer telehealth offering for weight loss in January 2024. Eli Lilly…